{
  "id": "6414c0f7690f196b51000001",
  "type": "list",
  "question": "What are the clinical symptoms of an ornithine transcarbamylase deficiency?",
  "ideal_answer": "The clinical symptoms of an ornithine transcarbamylase deficiency (OTC-D) can range from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. Common symptoms include extreme irritability, episodic vomiting and lethargy, protein avoidance, ataxia, Stage II coma, delayed physical growth, developmental delay, and seizures.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/36362876",
    "http://www.ncbi.nlm.nih.gov/pubmed/17845164",
    "http://www.ncbi.nlm.nih.gov/pubmed/3826955",
    "http://www.ncbi.nlm.nih.gov/pubmed/3945292",
    "http://www.ncbi.nlm.nih.gov/pubmed/36217298"
  ],
  "snippets": [
    {
      "text": "X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36362876",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ornithine transcarbamylase deficiency (OTC-D) is an X-linked metabolic disease and the most common urea cycle disorder. Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events to moderate symptoms and even asymptomatic individual",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36217298",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Deficiency of ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/3826955",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "extreme irritability (100 percent), episodic vomiting and lethargy (100 percent), protein avoidance (92 percent), ataxia (77 percent), Stage II coma (46 percent), delayed physical growth (38 percent), developmental delay (38 percent), and seizures",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/3945292",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ornithine transcarbamylase deficiency causes vomiting, lethargy, hyperventilation, and even death, mainly in the neonatal period.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17845164",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "seizures, developmental delay, hyperammonaemic encephalopathy, hyperammonemia,, delayed physical growth, Stage II coma, ataxia, protein avoidance, vomiting, lethargy, irritabilty"
}